Reply to the Letter to the Editor 'Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification' by Hannoun-Levi et al.

Franzoi, M A; Trapani, D; Jezdic, S; Regan, M M; Curigliano, G; Andre, F

Reply to the Letter to the Editor 'Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification' by Hannoun-Levi et al.

Franzoi, M A; Trapani, D; Jezdic, S; Regan, M M; Curigliano, G; Andre, F.

Afiliação

Franzoi MA; INSERM Unit 981 e Molecular Predictors and New Targets in Oncology, PRISM Center for Precision Medicine, Gustave Roussy, Villejuif, France.
Trapani D; Department of Medical Oncology, Dana-Farber Cancer Center, Boston, USA; Harvard Medical School, Boston, USA.
Jezdic S; Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland.
Regan MM; Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; New Drugs Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
Andre F; INSERM Unit 981 e Molecular Predictors and New Targets in Oncology, PRISM Center for Precision Medicine, Gustave Roussy, Villejuif, France.

Ann Oncol ; 33(12): 1331-1333, 2022 12.

Article em En | MEDLINE | ID: mdl-36115609

Assuntos

Neoplasias; Humanos; Neoplasias/terapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article